Gt biopharma advances gtb-3650, a second-generation tri-specific killer engager -trike®, into ind-enabling studies

Beverly hills, calif., sept. 13, 2021 /prnewswire/ -- gt biopharma, inc. (the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® protein biologic technology platform, today, announces the advancement of gtb-3650 into ind-enabling studies, with which it plans to supplant the ongoing phase 1 program with gtb-3550.
GTBP Ratings Summary
GTBP Quant Ranking